![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMIGD2 |
Gene summary for TMIGD2 |
![]() |
Gene information | Species | Human | Gene symbol | TMIGD2 | Gene ID | 126259 |
Gene name | transmembrane and immunoglobulin domain containing 2 | |
Gene Alias | CD28H | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q96BF3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
126259 | TMIGD2 | HCC1 | Human | Liver | HCC | 5.06e-09 | 8.57e-01 | 0.5336 |
126259 | TMIGD2 | HCC2 | Human | Liver | HCC | 1.18e-29 | 1.45e+00 | 0.5341 |
126259 | TMIGD2 | HCC5 | Human | Liver | HCC | 8.82e-44 | 1.98e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMIGD2 | SNV | Missense_Mutation | c.308N>T | p.Ser103Ile | p.S103I | Q96BF3 | protein_coding | deleterious(0.01) | possibly_damaging(0.637) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TMIGD2 | insertion | Frame_Shift_Ins | novel | c.176_177insCAGGG | p.Trp59CysfsTer46 | p.W59Cfs*46 | Q96BF3 | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TMIGD2 | insertion | Frame_Shift_Ins | novel | c.174_175insAGACAGAGTCTTGCTCTGTCGTCCAGGCCTTGGAG | p.Trp59ArgfsTer56 | p.W59Rfs*56 | Q96BF3 | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TMIGD2 | insertion | Nonsense_Mutation | novel | c.408_409insAAAAATACAAAAAATTAGCCAGACGTAGTAGCGG | p.Asp137LysfsTer6 | p.D137Kfs*6 | Q96BF3 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TMIGD2 | SNV | Missense_Mutation | c.183N>T | p.Lys61Asn | p.K61N | Q96BF3 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TMIGD2 | SNV | Missense_Mutation | rs761121311 | c.244N>A | p.Gly82Arg | p.G82R | Q96BF3 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
TMIGD2 | SNV | Missense_Mutation | c.302N>T | p.Pro101Leu | p.P101L | Q96BF3 | protein_coding | tolerated(0.7) | benign(0.003) | TCGA-AG-4007-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
TMIGD2 | SNV | Missense_Mutation | novel | c.749C>T | p.Pro250Leu | p.P250L | Q96BF3 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMIGD2 | SNV | Missense_Mutation | c.302N>A | p.Pro101His | p.P101H | Q96BF3 | protein_coding | tolerated(0.62) | benign(0.003) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMIGD2 | SNV | Missense_Mutation | rs371864498 | c.781G>A | p.Val261Ile | p.V261I | Q96BF3 | protein_coding | tolerated(0.17) | benign(0.026) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |